

Promoting Access to Medical Technologies and Innovation

SECOND EDITION

Intersections between public health, intellectual property and trade



Promoting Access to Medical Technologies and Innovation

Intersections between public health, intellectual property and trade

2nd Edition



Disclaimer

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion on the part of the World Health Organization (WHO), World Intellectual Property Organization (WIPO) or World Trade Organization (WTO) concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.

The mentioning of specific companies or products does not imply that they are endorsed or recommended by WHO, WIPO or WTO or preferred to others that are not mentioned. The names of proprietary products are usually distinguished by initial capital letters.

All reasonable precautions have been taken by WHO, WIPO and WTO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO, WIPO and WTO be liable for any consequences whatsoever arising from its use.

© World Trade Organization, World Health Organization and World Intellectual Property Organization, 2020

This document is freely available for redistribution under Creative Commons Attribution – Non Commercial – Share Alike (CC BY-NC-SA 3.0 IGO) public license to facilitate adoption and re-use. To view a copy of this license, please visit <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>. Adaptation/translation/derivatives should not carry any official emblem or logo. To reproduce this publication for commercial purposes, please contact WTO Publications.

WTO ISBN 978-92-870-4996-4 (print) / 978-92-870-4997-1 (electronic version)

WIPO ISBN 978-92-805-3174-9 Publication Number: 628E/20

WHO ISBN 978-92-4-000827-4 (print) / ISBN 978-92-4-000826-7 (electronic version)

This publication can be obtained through:

World Health Organization

Department of Public Health, Innovation and Intellectual Property
Avenue Appia 20
CH-1211 Geneva 27
Switzerland
Tel: + 41 22 791 21 11
Fax: + 41 22 791 31 11
Email: phidepartment@who.int
Website: www.who.int/phi/en/

World Intellectual Property Organization

WIPO Publications
Chemin des Colombettes 34
PO Box 18
CH-1211 Geneva 20
Switzerland
Tel: + 41 22 338 91 11
Email: publications.mail@wipo.int
Website: www.wipo.int/publications

World Trade Organization

WTO Publications
154 rue de Lausanne
CH-1211 Geneva 21
Switzerland
Tel: + 41 22 739 53 08
Fax: + 41 22 739 54 58
Email: publications@wto.org
Website: www.wto.org/Publications
Online WTO bookshop: <https://onlinebookshop.wto.org>

A PDF version of this publication is available on the websites indicated above.

Printed in Switzerland, 2020.

Publication designed by Book Now Ltd, London. Cover photos © Andrew Brookes / via Getty Images, Roxana Wegner / via Getty Images, lam Anupong / Shutterstock.com.

Contents

Acknowledgements	5
Foreword by the Directors-General	6
An integrated health, trade and IP approach to respond to the COVID-19 pandemic	7
Executive Summary	16

I. Medical technologies: the fundamentals 24

A. Public health and medical technologies: the imperative for international cooperation	26
1. Policy coherence	26
2. Scope of the study	27
3. The need for this study	27
4. Who should read this study?	28
B. The cooperating agencies: the WHO, WIPO and the WTO	29
1. World Health Organization	29
2. World Intellectual Property Organization	30
3. World Trade Organization	31
4. Trilateral cooperation	31
5. Other international key stakeholders	32
C. The global burden of disease and global health risks	33
1. Current estimates of global and regional burden of disease	33
2. Trends: major cause groups contributing to the total disease burden	33
3. Trends in global health risks	35
D. Factors shaping public health policy	36
1. Seeking effective outcomes within a complex policy environment	36
2. Transforming policy intersections	36
3. Building stronger links between local, national and global levels	37
4. The empirical challenge: an accessible base for policy	39

II. The policy context for action on innovation and access 42

A. Public health policy	44
1. Health and human rights	44
2. Access to essential medicines: an indicator for the fulfilment of the right to health	46
3. Universal access and the UN Sustainable Development Goals	46
4. Public health, innovation and access in the WHO	48
5. Cross-cutting efforts to tackle antimicrobial resistance	51
6. Regulation of health technologies	52

B. Intellectual property, trade and other policy dimensions	63
1. Intellectual property systems	63
2. Competition law and policy	95
3. Trade policy settings	98
4. Government procurement	103
5. Free trade agreements	105
6. Resolving trade disputes at the WTO	107
C. Economics of innovation and access to medical technologies	108
D. Genetic resources, traditional knowledge and traditional medicine	112
1. Traditional medicine knowledge systems	112
2. Traditional medical knowledge in health and IP policy	113
3. Traditional medicines regulation	113
4. Concerns about misappropriation of traditional knowledge and genetic resources	114
5. New approaches to IP protection of traditional medical knowledge	115
III. Medical technologies: the innovation dimension	130
A. Historical pattern of medical R&D	132
1. Innovation for medical technologies in context	132
2. From early discoveries to “wonder drugs”	132
3. Growth and evolution of the pharmaceutical industry	133
4. From non-exclusive licensing to restricted production	133
5. Trends in R&D	134
B. The current R&D landscape	138
1. A time of challenges and opportunities for pharmaceutical R&D	138
2. The key role of public-sector research in medical R&D	141
3. Medical R&D costs	142
4. Incentive models in the innovation cycle	143
5. Challenges in cancer medicines R&D	147
6. Orphan drugs and orphan indications	148
7. Registration of clinical trials in pharmaceutical product development	148
C. Overcoming market failures in medical product R&D	151
1. Diseases disproportionately affecting people in developing countries	151
2. Antimicrobials and antimicrobial resistance	152
3. The WHO R&D Blueprint for Action to Prevent Epidemics	154
4. WHO Expert Working Groups on R&D financing	155
5. Novel approaches to biomedical R&D	155
6. Product development partnerships	161
7. Research for neglected diseases: the role of pharmaceutical companies	163
8. WIPO Re:Search – Mobilizing intellectual property for global health	163

D. Intellectual property rights in the innovation cycle	166
1. IP management within the broader legal and policy framework at national and international levels	166
2. Intellectual property and the product development process	168
3. Patent filing strategies in the public and private sectors and the exercise of patent rights	168
4. Pre-grant issues: questions of patentability	169
5. Post-grant issues: questions related to the use of patents	176
E. Sharing of influenza viruses and access to vaccines and other benefits	180
1. WHO Global Influenza Surveillance and Response System	180
2. Intellectual property rights in the context of PIP negotiations	180
3. The PIP Framework	181
4. The PIP Framework and genetic sequence data	182
IV. Medical technologies: the access dimension	190
A. The context: health-systems-related determinants of access	192
1. Universal health coverage	193
2. International access frameworks: the value chain of medicines and health products	194
3. The meaning and measurement of “access”	195
4. Generic medicines policies, price controls and reference pricing	196
5. Taxes	203
6. Mark-ups	204
7. Rational selection and use of medicines	204
8. Effective and efficient procurement mechanisms	206
9. Sustainable financing	209
10. Manufacturing and technology transfer	209
11. Regulatory mechanisms and access to medical technologies	210
12. Substandard and falsified (SF) medical products	214
B. Access to health products in specific areas	217
1. HIV/AIDS	217
2. Antimicrobial resistance	219
3. Tuberculosis	220
4. Non-communicable diseases	221
5. Hepatitis C virus	224
6. Paediatric medicines	225
7. Vaccines	226
8. Medical devices	227
C. Intellectual-property-related determinants of access	229
1. Determinants of access prior to patent grant	230
2. Pre-grant and post-grant review procedures	232
3. Post-grant determinants of access	233

4. Patent information and its relationship with public health policy	252
5. Review of relevant provisions in free trade agreements	252
D. Other trade-related determinants of access	262
1. International trade and tariff data of health products	262
2. Competition law and policy	270

Annex I. Resolutions of the UN General Assembly and UN Human Rights Council Key Reports of the UN Special Rapporteur on the Right to Health

292

A. Selected Resolutions of the United Nations General Assembly	294
B. Selected Resolutions of the United Nations Human Rights Council	295
C. Key Reports of the United Nations Special Rapporteur on the Right to Health	296

Annex II. Selected Resolutions and Decisions of the World Health Assembly

298

Annex III. Special Compulsory Licences for Export of Medicines

302

A. Operation of the System: context and scope	304
B. Legal basis	304
C. Use of the System	304
D. Domestic implementation	307

Bibliography	310
Abbreviations	329
List of figures, tables and boxes	334
Extended table of contents	339

Acknowledgements

This publication is the product of extensive collaboration between the WHO, WIPO and WTO Secretariats, led by the Department of Public Health, Innovation and Intellectual Property in the WHO, the Global Challenges Division in WIPO and the Intellectual Property, Government Procurement and Competition Division in the WTO.

Research, authoring and substantive review was done by: Hans Georg Bartels, Peter Beyer, Erika Dueñas, Dzintars Gotham, Roger Kampf, Nancy Pignataro, Charles Randolph, Antony Taubman and Jayashree Watal.

The contribution of many others are warmly acknowledged, in particular: Daniel Glenn Adams, Marco Aleman, Lucie Archambeau, Andrea Arce Gallardo, Aditi Bana, Tobias Bednarz, Shakeel Bhatti, Thomas Bombelles, Mathew Bryan, Denis Cohen, Andrew Czajkowski, Cynthia Dapaah, Amy Dietterich, Aida Dolotbaeva, Jicui Dong, Nicole Drews, Edward Elliott, Carsten Fink, Gilles Forte, Martin Howell Friede, Martha Parra de Friedli, Dimitre Gantchev, Minelik Alemu Getahun, Trevor Gunn, Jorge Gutierrez, Anneke Hamilton, Dalila Hamou, Nicole

Homb, Anne Marie Huvos, Fei Jiao, Aegyoung Jung, Mosahid Khan, Irene Kitsara, Arne Klau, Daniel Ismael López Salcedo, Geidy Lung, Wahyu Retno Mahanani, Joscelyn Magdeleine, Allison Mages, Nicola Magrini, Darlan Marti, Christophe Mazenc, Maegan McCann, Devin McDaniels, Tanvi Misra, Tomoko Miyamoto, Ali Akbar Modabber, Anna Caroline Müller, Benoît Müller, Giovanni Napolitano, Sergio Napolitano, Harrison Hunter Ottaway, Josefita Pardo de Leon, Philippe Pelletier, Mansur Raza, Alex Riechel, Andrew Rintoul, Alejandro Roca Campaña, Debbie Roenning, Robina Sandhu, Vasee Sathiyamoorthy, Nadezhda Sporysheva, Catherina Maria E. Timmermans, Adriana Velazquez Berumen, Lien Verbauwhede, Thomas Verbeet, Xavier Vermandele, Hannu Wager, Max Wallot, Victoria Weyulu, Michele Woods, Sacha Wunsch-Vincent, Ning Xu, Young-Woo Yun and Qi Zhang.

Special thanks for editorial and administrative support are due to: Charlotte Beauchamp, Stephanie Carmel, Bassam Peter Khazin, Anthony Martin, Veronica Pini Scerbo, Jenny Rouse, and Heather Sapey-Pertin.

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_24466

